Search results for: 'Radar Support Frost Radar: Low-Code Application Platforms'

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

Today, the journey of starting a family does not look the way it did fifty years ago, and people are turning to fertility services for help. 1 in 8 couples in the United States experience pregnancy-related difficulties that fertility treatments can address. Key market drivers include the increasing rate of obesity causing deterred ovulation in wom...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

16 Feb 2021  |  North America  |  Market Research

Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market

Mobility Ecosystem Holds Bold Promise to Expand Patients’ Access to Care

Infographics

×

Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics. The global COVID-19 pandemic has led to frugal innovations in POCT. The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak. Digital...

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry. The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recen...